莫西沙星+头孢哌酮钠舒巴坦钠对肺脓肿患者的临床效果及安全性分析  

Analysis of clinical effect and safety of moxifloxacin and cefoperazone sodium and sulbactam sodium in patients with pulmonary abscess

作　　者：徐金平 XU Jin-ping(Jinxiang County People's Hospital,Jining 272200,China)

机构地区：[1]金乡县人民医院,272200

出　　处：《中国实用医药》2024年第16期30-33,共4页China Practical Medicine

摘　　要：目的探讨肺脓肿患者应用莫西沙星与头孢哌酮钠舒巴坦钠联合治疗的效果及安全性。方法60例肺脓肿患者,采用随机数字表法分为对照组和观察组,各30例。对照组采用头孢哌酮钠舒巴坦钠治疗,观察组在对照组治疗基础上联合莫西沙星治疗。比较两组临床疗效、康复状况、炎症指标及不良反应发生情况。结果观察组总有效率高于对照组(93.33%>73.33%)(P<0.05)。治疗后,观察组咳嗽缓解时间、体温及白细胞恢复正常时间、住院时间分别为(8.43±2.13)、(6.73±1.45)、(19.73±1.62)、(29.13±1.27)d,均短于对照组的(13.48±2.45)、(7.83±1.67)、(23.23±1.86)、(35.29±1.36)d(P<0.05)。治疗后,观察组C反应蛋白(6.39±1.02)mg/L及白细胞计数(7.27±1.01)×10^(9)/L均低于对照组的(8.51±1.06)mg/L、(8.91±1.75)×10^(9)/L(P<0.05)。观察组不良反应发生率低于对照组(6.67%<10.00%),但差异无统计学意义(P>0.05)。结论莫西沙星与头孢哌酮钠舒巴坦钠联合治疗肺脓肿患者效果显著,并且具有较高的安全性,值得临床推广应用。Objective To explore the effect and safety of moxifloxacin and cefoperazone sodium and sulbactam sodium in patients with pulmonary abscess.Methods A total of 60 patients with pulmonary abscess were divided into a control group and an observation group according to random numerical table method,each with 30 cases.The control group received treatment with cefoperazone sodium and sulbactam sodium,while the observation group received treatment with moxifloxacin on the basis of the control group.The clinical efficacy,rehabilitation status,inflammatory markers,and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group(93.33%>73.33%)(P<0.05).After treatment,the time of cough remission,the recovery time of body temperature and white blood cell,and the time of hospitalization in the observation group were(8.43±2.13),(6.73±1.45),(19.73±1.62),and(29.13±1.27)d,which were shorter than(13.48±2.45),(7.83±1.67),(23.23±1.86),and(35.29±1.36)d in the control group(P<0.05).After treatment,the observation group had C-reactive protein of(6.39±1.02)mg/L and white blood cell count of(7.27±1.01)×10^(9)/L,which were lower than(8.51±1.06)mg/L and(8.91±1.75)×10^(9)/L in the control group(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group(6.67%<10.00%),but the difference was not statistically significant(P>0.05).Conclusion The combination of moxifloxacin and cefoperazone sodium and sulbactam sodium has a significant effect on the treatment of pulmonary abscess patients and has high safety.It is worthy of clinical promotion.

关 键 词：莫西沙星 头孢哌酮钠舒巴坦钠 肺脓肿 临床疗效 安全性 

分 类 号：R563.2[医药卫生—呼吸系统]